Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of mRNA-1345 Coadministered with Fluzone HD in Older Adults
NCT06060457Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Sep 2023
- Primary completion
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of RNA-100-AR02 in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Moderna Inc. Primary endpoints: Number of Participants With Solicited Local and Systemic Adverse Reactions, Number of Participants With Unsolicited Adverse Events and 3 more. Started Sep 2023; status: completed.
02
Drugs
RNA-100-AR02
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06060457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06060457.